Cytori Extends Distribution Agreement with GE Healthcare; Key Focus on Research Market
Cytori Therapeutics, Inc. (NASDAQ:CYTX) has extended the term and modified the focus of its current distribution agreeme…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) has extended the term and modified the focus of its current distribution agreeme…
Cytori Therapeutics (NASDAQ: CYTX) has received U.S. Patent No. 7,771,716 (the '716 patent) for Celution(R) System based…
Cytori Therapeutics (Nasdaq:CYTX) reports second quarter and first half 2010 financial results. Further details, includi…
Cytori Therapeutics (NASDAQ: CYTX) received expanded European approval (CE Mark) for its Celution(R) System, a medical d…
Interim results from a breast reconstruction trial show stem and regenerative cellenriched fat grafting resulted in a hi…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) closed and received net proceeds from the definitive agreements the Company ente…
Cytori Therapeutics, Inc. (NASDAQ: CYTX) entered into definitive agreements to raise $10 million, before placement agent…
Cytori Therapeutics, Inc. (NASDAQ: CYTX) completed enrollment in its APOLLO trial to evaluate the safety and feasibility…